[go: up one dir, main page]

CY1112973T1 - Περαιτερω κρυσταλλικες μορφες ροσταφουροξινης - Google Patents

Περαιτερω κρυσταλλικες μορφες ροσταφουροξινης

Info

Publication number
CY1112973T1
CY1112973T1 CY20121100330T CY121100330T CY1112973T1 CY 1112973 T1 CY1112973 T1 CY 1112973T1 CY 20121100330 T CY20121100330 T CY 20121100330T CY 121100330 T CY121100330 T CY 121100330T CY 1112973 T1 CY1112973 T1 CY 1112973T1
Authority
CY
Cyprus
Prior art keywords
rostafouroxin
crystal forms
further crystal
forms
βandrostane
Prior art date
Application number
CY20121100330T
Other languages
English (en)
Inventor
Alberto Cerri
Silvia Armaroli
Maco Torri
Original Assignee
Rostaquo S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rostaquo S.P.A. filed Critical Rostaquo S.P.A.
Publication of CY1112973T1 publication Critical patent/CY1112973T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Περιγράφονται νέες κρυσταλλικές μορφές 17β-(3-Φουρυλ)-5-β-ανδροστανε-3β, 14β, 17α-τριόλης μαζί με φαρμακευτική σύνθεση που περιέχει τις ίδιες και μεθόδους για την παρασκευή τους. Συγκεκριμένα περιγράφονται στο παρόν οι νέες Μορφές B,C,D,E, και H.
CY20121100330T 2005-11-25 2012-04-03 Περαιτερω κρυσταλλικες μορφες ροσταφουροξινης CY1112973T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05025817 2005-11-25
EP06819722A EP1951738B1 (en) 2005-11-25 2006-11-23 Further crystalline forms of rostafuroxin

Publications (1)

Publication Number Publication Date
CY1112973T1 true CY1112973T1 (el) 2016-04-13

Family

ID=36165370

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100330T CY1112973T1 (el) 2005-11-25 2012-04-03 Περαιτερω κρυσταλλικες μορφες ροσταφουροξινης

Country Status (10)

Country Link
US (1) US9127037B2 (el)
EP (1) EP1951738B1 (el)
AT (1) ATE541855T1 (el)
CY (1) CY1112973T1 (el)
DK (1) DK1951738T3 (el)
ES (1) ES2380491T3 (el)
PL (1) PL1951738T3 (el)
PT (1) PT1951738E (el)
SI (1) SI1951738T1 (el)
WO (1) WO2007060206A2 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010149666A1 (en) 2009-06-22 2010-12-29 Medexis S.A. Methods for treating neoplasia
EA201270574A1 (ru) * 2009-10-19 2012-12-28 Ростакуо С.П.А. Способы и системы для фармакогеномного лечения сердечно-сосудистых заболеваний
US20130295100A1 (en) 2010-11-19 2013-11-07 Ospedale San Raffaele S.R.L. Markers for acute kidney injury and uses thereof
CN102940640A (zh) * 2012-12-06 2013-02-27 中国生命药物治疗有限公司 罗他夫辛在制备治疗基因缺陷型原发性高血压的药物中的用途
CN108096207B (zh) * 2017-12-29 2021-01-01 兆科药业（合肥）有限公司 一种罗他夫辛肠溶片的制备方法
US11337988B2 (en) 2018-09-27 2022-05-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of ouabain antagonists to inhibit viral infection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4221636C1 (de) * 1992-07-01 1994-03-31 Sigma Tau Ind Farmaceuti Cyclopentanperhydrophenanthren-17beta-(3-furyl)-3-Derivate
DE4227616C2 (de) 1992-08-20 1995-04-13 Sigma Tau Ind Farmaceuti 17-(3-Furyl)-und 17-(4-Pyridazinyl)-5beta, 14beta-androstanderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammemsetzungen
IT1282286B1 (it) * 1995-05-11 1998-03-16 Sigma Tau Ind Farmaceuti Seco-d steroidi sul sistema cardiovascolare, processi per la loro preparazione e composizioni farmaceutiche che li contengono.

Also Published As

Publication number Publication date
WO2007060206A3 (en) 2007-08-30
ES2380491T3 (es) 2012-05-14
WO2007060206A2 (en) 2007-05-31
EP1951738B1 (en) 2012-01-18
US20080300228A1 (en) 2008-12-04
SI1951738T1 (sl) 2012-06-29
US9127037B2 (en) 2015-09-08
PL1951738T3 (pl) 2012-06-29
DK1951738T3 (da) 2012-04-23
EP1951738A2 (en) 2008-08-06
ATE541855T1 (de) 2012-02-15
PT1951738E (pt) 2012-04-18

Similar Documents

Publication Publication Date Title
CY2018013I2 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
BRPI0720124A2 (pt) Composições farmacêuticas e seus métodos de uso.
MY148635A (en) Anti-tat226 antibodies and immunoconjugates
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
MX2009003938A (es) Anticuerpos e inmunoconjugados y sus usos.
ECSP078055A (es) Formas sólidas cristalinas de tigeciclina y métodos para preparar las mismas
MX359639B (es) Metodos y composiciones para uso en tratamientos celulares.
GT200600264A (es) Modificaciones cristalinas de piraclostrobina
TW200732349A (en) Anti-OX40L antibodies and methods using same
CY1112511T1 (el) Κρυσταλλικη στερεα βαση ρασαγιλινης (rasagiline)
BRPI0607279A2 (pt) composição compatìvel com fertilizante
IL192631A (en) A drug containing an isolated antibody or a functional portion thereof, pharmaceutical preparations and a kit containing it
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
BRPI0819299A2 (pt) Uso de composição, e, composição contendo proteína
CY1112973T1 (el) Περαιτερω κρυσταλλικες μορφες ροσταφουροξινης
HN2006011218A (es) Composiciones de tigeciclina y métodos de preparación
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
BRPI0813587A2 (pt) Composto, uso do mesmo, e, composição farmacêutica
WO2008021250A3 (en) Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
BRPI0606132A2 (pt) formas cristalinas de docetaxel e processos para seu preparo
BRPI0911772A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0720323A2 (pt) composto, método de tratamento, composição farmacêutica e uso do composto
EP1637167A3 (en) New injectable formulations containing progesterone